1. Home
  2. PMAX vs SNOA Comparison

PMAX vs SNOA Comparison

Compare PMAX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMAX

Powell Max Limited

HOLD

Current Price

$1.58

Market Cap

3.7M

Sector

N/A

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$1.22

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
SNOA
Founded
2019
1999
Country
Hong Kong
United States
Employees
53
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
4.0M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
PMAX
SNOA
Price
$1.58
$1.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
189.1K
86.6K
Earning Date
05-12-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.26
EPS
N/A
N/A
Revenue
N/A
$19,529,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.68
52 Week Low
$0.20
$0.85
52 Week High
$5.20
$6.92

Technical Indicators

Market Signals
Indicator
PMAX
SNOA
Relative Strength Index (RSI) 35.99 56.95
Support Level $0.24 $1.02
Resistance Level $2.79 $1.25
Average True Range (ATR) 0.26 0.07
MACD -0.07 0.02
Stochastic Oscillator 5.37 81.41

Price Performance

Historical Comparison
PMAX
SNOA

About PMAX Powell Max Limited

Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: